swty123.com • Professional Insights • Expert Commentary • Resource Center
swty123.com

dipeptide glu-lys New Trends,global supplier of Pleiotrophin (Human

Understanding the Dipeptide Glu-Lys: Structure, Synthesis, and Applications Description. Melanoma peptideused to measure the binding of MAGE3 (Melanoma Associated Angigen 3) peptidesto HLA-B44 molecules.

dipeptide glu-lys

dipeptide glu-lys:Glu-Lys is a polypeptide that can be found by peptide screening

A
Judith Barnes

studies 'dipeptide glu-lys' data patterns and performance metrics and publishes well-organized content through Medium and LinkedIn

Published on

Executive Summary

dipeptide glu-lys The structure of Glu-Lys-Ala is shown below Description. Melanoma peptideused to measure the binding of MAGE3 (Melanoma Associated Angigen 3) peptidesto HLA-B44 molecules.

The dipeptide glu-lys, a compound formed by the linkage of L-glutamic acid and L-lysine, is a molecule of significant interest in various scientific disciplines. This article delves into the fundamental aspects of this dipeptide, exploring its chemical structure, methods for synthesizing dipeptide with glutamic acid as the first amino acid residue, and its emerging applications. Understanding the properties of glu-lys is crucial for researchers and developers working with peptides, from fundamental biochemical studies to the development of novel therapeutics and materials.

The Molecular Architecture of Glu-Lys

At its core, the dipeptide glu-lys is characterized by a peptide linkage formed between the carboxyl group of glutamic acid and the amine group of lysine. This linkage results in a molecule with the chemical formula C11H21N3O5. The sequence can exist in two primary forms: Glu-Lys (where glutamic acid precedes lysine) and Lys-Glu (where lysine precedes glutamic acid). These sequences can influence the overall properties and interactions of the dipeptide.

It's important to distinguish between the common alpha-peptide linkage and other potential bonding arrangements. For instance, the y-Glu-Lys (L-y-Glutamyl-L-lysine) represents a y-glutamyl dipeptide, where the peptide bond is formed via the gamma-carboxyl group of glutamic acid. This structural variation can lead to distinct biochemical activities and is relevant in understanding the broader landscape of Lys-Glu derivatives.

The presence of charged amino acid residues, lysine (which is basic) and glutamic acid (which is acidic), makes glu-lys an amphoteric molecule. This ampholytic nature means its charge state is pH-dependent. Understanding how to draw the di-peptide Glu-Lys at neutral pH requires considering the pKa values of the amino and carboxyl groups, as well as the side chains of both amino acids. This pH-dependent behavior is critical for its solubility, interactions, and biological activity.

Synthesis and Availability of Glu-Lys

The synthesis of dipeptide glu-lys can be achieved through various established peptide synthesis methodologies. Solid-phase peptide synthesis (SPPS) is a common technique, allowing for the sequential addition of amino acids to a solid support. This approach is particularly useful for creating more complex peptides and peptide analogs, such as dipeptide building block for SPPS synthesis of Semaglutide, a GLP-1 analogue.

For researchers requiring specific dipeptides for experimental purposes, commercial availability is a key factor. Companies offer various forms, including high-purity reference standards. For example, the Lys-Glu dipeptide CRB1000469 is available for pharmaceutical testing. Similarly, the KD20 peptide, with the sequence H-KE-OH, is offered with a purity greater than 95% and a molecular weight of 275.1 g/mol. The availability of specific sequences like Glu-Lys-Gly (with formula C13H24N4O6) further expands the research possibilities.

Beyond simple dipeptides, more complex structures incorporating glu-lys motifs are also synthesized. Examples include L-Ala-D-Glu-gamma-L-Lys-D-Ala-D-Ala, a peptidoglycan pentapeptide relevant in immunological studies, and peptide glu-lys-asp-cys-leu, a sequence involving other amino acids like aspartic acid, cysteine, and leucine. These complex peptides highlight the versatility of glu-lys as a building block.

Applications and Emerging Roles of Glu-Lys

The scientific literature reveals a growing number of applications and areas of research involving the dipeptide glu-lys and its related structures.

One significant area of investigation is the role of Lys-Glu in modulating immune responses. Studies have shown that Lys-Glu in vitro stimulated interleukin-2 gene expression in mouse spleen lymphocytes. This effect is concentration-dependent and suggests a potential role for this dipeptide in immune system regulation. Furthermore, specific peptide sequences containing Lys-Glu, such as the anterior pituitary peptide Lys-Glu-Asp-Gly, have been studied for their effects on thymic structure and hormonal regulation in aging organisms.

The ampholytic nature of glu-lys also contributes to its interesting properties. For instance, it has been observed that peptides can exhibit detergent-like activity, creating defects in lipid bilayers. This characteristic is seen in molecules like bovine lactoferricin, which interacts strongly with bacterial membranes, and suggests that dipeptides and polypeptides incorporating glu-lys could possess antimicrobial or membrane-interacting properties.

In the realm of materials science and drug development, glu-lys serves as a foundational element. As mentioned earlier, it's a component in the synthesis of advanced peptide-based therapeutics like Semaglutide. The development of dipeptide building block for SPPS synthesis of Semaglutide underscores the importance of precise dipeptide synthesis for creating sophisticated drug molecules

Related Articles

Frequently Asked Questions

Here are the most common questions about dipeptide glu-lys.

Ala-D-γ-Glu-Lys-D-Ala-D-Alais the pentapeptide tail of the peptidoglycan precursor UDPMurNAc-l-Ala-γ-d-Glu-l-Lys(Gly)(5)-d
Effects of Peptides Lys-Glu-Asp-Gly and Ala - Springer Nature
Dipeptide building block for SPPS synthesis of Semaglutide(brand name Ozempic). Semaglutide is a GLP-1 analogue and has been developed in 2012 by Novo Nordisk 
Ala-D-γ-Glu-Lys-D-Ala-D-Ala | Peptidoglycan pentapeptide

Leave a Comment

Share your thoughts, feedback, or additional insights on this topic.

Explore More